الفهرس 
Diabetes mellitusOnly 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Diabetes mellitus is the most important factor for large vessels atherosclerotic occlusive disease, diabetic patients have two to four folds increase in risk of developing PVD more than non-diabetic individuals.
Fetuin-A is a glycoprotein carries two N-linked and three O-linked oligosaccharide chains that terminate with sialic acid residues, and can bind cationic Ca2+ ions. Accordingly, fetuin- A has been proposed as an endogenous inhibitor of pathological mineralization or calcification in soft tissues. Specifically, fetuin-A forms protein-mineral colloids with calcium and phosphate, thereby preventing uncontrolled mineralization that may otherwise occur under pathological conditions.
Aim of this study is to evaluate the association of plasma fetuin-A and peripheral vascular disease in type 2 diabetic patients.
This study was conducted on twenty type 2 diabetic patients with peripheral vascular disease (PVD), twenty type 2 diabetic patients without peripheral vascular disease (PVD), all are selected from the inpatient department in the national institute of diabetes and endocrinology (NIDE), and ten healthy controls. The age group of all subjects is ranged from fifty to sixty five.
Using ELISA technique, the mean fetuin-A level was (133.690 ± 32.083) ng/ ml in group (1), (248.395 ± 75.296) ng/ml in group (2), (310.760 ± 106.876) ng/ml in group (3).
Doing Doppler ultrasound on the peripheral arteries in all subjects, the mean APSV (Ankle Peak Systolic Velocity) was (19.000 ± 2.714) cm/s in group (1), (81.450 ± 5.031) cm/s in group (2), (117.600 ± 17.264) cm/s in group (3).
There was a highly statistical significant decrease in plasma fetuin-A levels being lower in group (1) (diabetics with PVD) than group (2) (diabetics without PVD) and group (3) (controls).
CONCLUSION
There is an association between lower plasma fetuin-A level and peripheral vascular disease in type 2 diabetic patients.
RECOMMENDATION
Further study designs are needed to evaluate the role of plasma fetuin-A levels in development of PVD in diabetic patients and the role of fetuin-A in other complications of diabetes such as ischemic heart disease and diabetic nephropathy and the relation between fetuin-A and insulin resistence. Also, more patients and controls are needed for better representation and interpretation.